Drug combination and radiation for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (cadonilimab and anlotinib) followed by radiation therapy for esophageal cancer that has returned or spread. The goal is to see if this approach helps shrink tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of esophageal cancer called squamous cell carcinoma that has either come back or spread to other parts of the body.
- You can join if you have not had treatment for this cancer yet, or if previous treatment stopped working.
- You need to be 18 years or older and generally able to take care of yourself (ECOG 0-2).
- You must have at least one tumor that can be seen on a scan.
- Your blood counts and organ function (liver, kidneys, thyroid, heart) need to be within acceptable levels.
- If you previously had immunotherapy, you must not have had severe side effects that required stopping the treatment permanently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.
This trial is testing a combination of two drugs (cadonilimab and anlotinib) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
This trial tests a combination of targeted radiation (SBRT) and an immunotherapy drug (AK104) for people with esophageal squamous cell cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a combination of three medications—chidamide, camrelizumab, and apatinib—for people with advanced esophageal cancer. The goal is to see if this combination can help control the cancer and potentially improve outcomes for patients who have received prior treatments.
This trial tests a combination of three drugs—becotatug vedotin, tislelizumab, and low-dose lenvatinib—for people with advanced esophageal cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.